Anti-CD19 [B4]

Absolute Antibody

Anti-CD19 [B4]

7

This antibody is recommended to be used for the cell surface expression of the B4 antigen. It is reported that in mitogen stimulated B cells the expression of the B4 antigen increases initially with the B cell activation and then is lost with the B cell differentiation (PMID: 6408173). Conjugate of DC1 with murine and humanizsed versions of anti-B4 antibody was found to be potent and effective in selective killing of target cells in culture. It is also reported that the anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals hearing large tumors (PMID: 7545085). Anti-B4 when conjugated with blocked ricin increased the antibody induced cell calcium mobilization and CD19 internalization. Modulation of CD19 induced by anti-B4 or anti-B4-bR was evaluated by indirect immunofluoresecence and flow cytometry (PMID: 9310487). Anti-B4-blocked ricin (anti-B4-bR) recognizes CD19-positive cells, which includes most B-cell non-Hodgkins lymphomas (NHLs). Phase II clinical studies of anti-B4-bR suggested that it does not actively penetrate in certain sites of the disease and is not an active agent in relapsed NHLs (PMID: 9829722)

Flow Cytometry, ImmunoFluorescence, ImmunoHistoChemistry

IF; FC; IHC

Research Use Only

Monoclonal

B4

CD19

CD19 molecule

B4, CVID3, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12, differentiation antigen CD19

Mouse

IgG1

B-lymphocyte antigen CD19

Human

The original antibody was generated against CD19 antigen present on human B cells.

-20°C,2°C to 8°C

12352203